Astrocytoma - Pipeline Review, H2 2011Global Markets DirectAugust 31, 2011 152 Pages - SKU: GMD6506158 |
|
Obsessive-Compulsive Disorder – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
Obsessive-Compulsive Disorder – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Obsessive-Compulsive Disorder - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Obsessive-Compulsive Disorder,
|
read more...
|
$2,000.00
|
|
Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides
|
read more...
|
$2,000.00
|
|
Brain Ischemia – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
Brain Ischemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Brain Ischemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Brain Ischemia,
|
read more...
|
$2,000.00
|
|
Malignant Glioma – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
Malignant Glioma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma,
|
read more...
|
$2,000.00
|
|
Tinnitus – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
Tinnitus – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Tinnitus - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tinnitus, complete with latest
|
read more...
|
$2,000.00
|
|
High-Grade Glioma – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
High-Grade Glioma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'High-Grade Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for High-Grade Glioma,
|
read more...
|
$2,000.00
|
|
Recurrent Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2013
5/27/2013 | published by: Global Markets Direct
Recurrent Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic
|
read more...
|
$2,000.00
|
|
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment
4/30/2013 | published by: GBI Research
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment Summary GBI Research, the leading business intelligence provider, has released its latest research “ADHD Therapeutics Market to 2018
|
read more...
|
$3,500.00
|
|
The Depression Market Forecast to 2021
4/25/2013 | published by: Datamonitor
The Depression Market Forecast to 2021
Introduction
Datamonitor Healthcare values the depression market, comprising of traditional major depressive disorder, as well as treatment-resistant major depression and dysthymia, at $5.6bn
|
read more...
|
$8,000.00
|
|
Tourette Syndrome – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
Tourette Syndrome – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Tourette Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tourette Syndrome,
|
read more...
|
$2,000.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
CNS/Neurology Reports